FC
GILD icon

Fairscale Capital’s Gilead Sciences GILD Stock Holding History

Fairscale Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.35K Hold
74
– – 0.01% 320
2026
Q1 		$10.3K Hold
74
– – 0.01% 312
2025
Q4 		$9.08K Hold
74
– – 0.01% 304
2025
Q3 		$8.21K Hold
74
– – 0.01% 337
2025
Q2 		$8.31K Buy
74
+58
+363% +$6.17K 0.01% 336
2025
Q1 		$1.79K Hold
16
– – ﹤0.01% 306
2024
Q4 		$1.48K Hold
16
– – ﹤0.01% 316
2024
Q3 		$1.34K Hold
16
– – ﹤0.01% 316
2024
Q2 		$1.15K Buy
+16
New +$1.07K ﹤0.01% 328

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fairscale Capital's GILD Position: Q2 2026 in Review

Fairscale Capital held its Gilead Sciences (GILD) position steady in Q2 2026 at 74 shares worth $9.35K. The position accounts for 0.01% of the portfolio, ranked #320.

Fairscale Capital first reported a position in GILD in Q2 2024 and has held it in 9 quarters since. The position peaked at $10.3K in Q1 2026. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Fairscale Capital held 74 shares of Gilead Sciences worth $9.35K as of Q2 2026.
  • Fairscale Capital left its Gilead Sciences share count unchanged in Q2 2026.
  • Gilead Sciences made up 0.01% of Fairscale Capital's portfolio in Q2 2026, its #320 holding.
  • Fairscale Capital first reported a position in Gilead Sciences in Q2 2024 and has held it in 9 quarters since.
  • Fairscale Capital's Gilead Sciences position peaked at $10.3K in Q1 2026.
  • 2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Fairscale Capital's 13F filing for Q2 2026, filed 7 Aug 2026.